What Is Enclomiphene?
Enclomiphene is an oral, non-steroidal selective estrogen receptor antagonist (SERM) used to raise endogenous testosterone by blocking estrogen's negative feedback at the hypothalamus and pituitary. Unlike injectable testosterone replacement therapy (TRT), which suppresses the HPG axis and shuts down natural production, enclomiphene stimulates the body's own testosterone pathway — preserving testicular function and spermatogenesis.
Enclomiphene is the trans-isomer of clomiphene citrate, isolated to separate its anti-estrogenic effects from the pro-estrogenic zuclomiphene (cis-isomer) found in standard clomiphene. This distinction matters clinically: the zuclomiphene isomer in standard clomiphene is associated with mood disturbances, visual side effects, and estrogen-driven complications that enclomiphene largely avoids.
Mechanism of Action
Enclomiphene occupies estrogen receptors in the hypothalamus, preventing estrogen from exerting its normal negative feedback signal that would ordinarily reduce GnRH output. With this feedback disrupted, the hypothalamus increases GnRH secretion, which drives the pituitary to release more LH and FSH. Elevated LH stimulates Leydig cells to produce more testosterone; elevated FSH supports Sertoli cell function and spermatogenesis.
A key mechanistic note: some sources describe enclomiphene as acting like a GnRH receptor agonist at the hypothalamus, but the more consistently supported mechanism across clinical literature is estrogen receptor antagonism upstream of GnRH release. The net result is the same — increased pituitary gonadotropin output — but the distinction matters for understanding interaction effects with other HPG axis agents.
Enclomiphene vs. Gonadorelin and HMG: Key Distinctions
Enclomiphene sits alongside Gonadorelin and HMG as options for HPG axis support, but it operates by a fundamentally different mechanism:
- Enclomiphene (oral SERM): Works upstream by blocking estrogen's negative feedback at the hypothalamus. The only oral option among the three. Requires an intact hypothalamus and pituitary to produce effect. Commonly used as a standalone TRT alternative.
- Gonadorelin (GnRH analog): Replaces hypothalamic GnRH signaling directly at the pituitary. Requires pulsatile injection dosing. Less reliable when pituitary gonadotroph function is suppressed by exogenous androgens.
- HMG (FSH + LH): Bypasses the hypothalamus and pituitary entirely by providing direct gonadotropin activity. Most reliable when pituitary is suppressed; no oral option available.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Wiehle RD, et al. (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Reprod Syst Sex Disord.
- Kim ED, et al. (2016). Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men. Fertil Steril.
- Helo S, et al. (2015). A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med.
- Redmon JB, et al. (2008). Efficacy and safety of enclomiphene citrate for the treatment of secondary hypogonadism. Clin Endocrinol (Oxf).